Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03589469 · BASELINE

Baseline characteristics

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Source last updated 2023-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      145
    units
    Participants
groups
  1. description
    Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.
    id
    BG000
    title
    Loncastuximab Tesirine
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          13.63
          value
          62.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          60
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          85
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          13
        title
        Hispanic or Latino
      2. measurements
        1. group Id
          BG000
          value
          132
        title
        Not Hispanic or Latino
      3. measurements
        1. group Id
          BG000
          value
          0
        title
        Unknown or Not Reported
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Ethnicity (NIH/OMB)
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          130
        title
        White
      2. measurements
        1. group Id
          BG000
          value
          5
        title
        Black or African American
      3. measurements
        1. group Id
          BG000
          value
          3
        title
        Asian
      4. measurements
        1. group Id
          BG000
          value
          1
        title
        American Indian or Alaskan Native
      5. measurements
        1. group Id
          BG000
          value
          1
        title
        Native Hawaiian or Pacific Islander
      6. measurements
        1. group Id
          BG000
          value
          5
        title
        Other
      title
      Race
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          59
      title
      United States
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          31
      title
      United Kingdom
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          53
      title
      Italy
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Switzerland
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Region of Enrollment
    unit Of Measure
    Participants
population Description
All-treated population - all participants who received at least 1 dose of treatment.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      145
    units
    Participants
groups
  1. description
    Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.
    id
    BG000
    title
    Loncastuximab Tesirine
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          13.63
          value
          62.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          60
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          85
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          13
        title
        Hispanic or Latino
      2. measurements
        1. group Id
          BG000
          value
          132
        title
        Not Hispanic or Latino
      3. measurements
        1. group Id
          BG000
          value
          0
        title
        Unknown or Not Reported
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Ethnicity (NIH/OMB)
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          130
        title
        White
      2. measurements
        1. group Id
          BG000
          value
          5
        title
        Black or African American
      3. measurements
        1. group Id
          BG000
          value
          3
        title
        Asian
      4. measurements
        1. group Id
          BG000
          value
          1
        title
        American Indian or Alaskan Native
      5. measurements
        1. group Id
          BG000
          value
          1
        title
        Native Hawaiian or Pacific Islander
      6. measurements
        1. group Id
          BG000
          value
          5
        title
        Other
      title
      Race
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          59
      title
      United States
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          31
      title
      United Kingdom
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          53
      title
      Italy
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Switzerland
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Region of Enrollment
    unit Of Measure
    Participants
population Description
All-treated population - all participants who received at least 1 dose of treatment.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice